Safety and immunogenicity of 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase II clinical trial in Europe

Архивировано 04.10.2021: escmid-2019-P0339.pdf

Источник: Thiebaut R., et al. Safety and immunogenicity of 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase II clinical trial in Europe. ESCMID, 2019, P0339

The Ad26, MVA vaccine regimens were found to be well tolerated and immunogenic. Binding antibody responses persisted at least up to one year post-dose 1. This study supports the further development of Ad26, MVA heterologous 2-dose vaccination for the prevention of Ebola Virus Disease